Each strip contains precisely measured doses for consistent, reliable results
BPC-157s anti-inflammatory activity is documented in GI (IBD, NSAID-injury), systemic (endotoxaemia, sepsis models), musculoskeletal (tendon, muscle), and CNS (neuroinflammation) contexts

How it helps disc herniation specifically: Upregulates tendon-related growth factors BPC-157 activates the Egr-1 transcription factor, which drives collagen synthesis in fibrous tissue including the annulus fibrosus Promotes angiogenesis increases VEGF expression, improving blood supply to the avascular disc environment Neuroprotective effects multiple rodent studies show BPC-157 accelerates peripheral nerve regeneration and protects against nerve compression injury Systemic anti-inflammatory suppresses pro-inflammatory cytokine cascades without the immunosuppressive side effects of steroids Protocol: Dose: 250500mcg/day subcutaneous injection Injection site: Lower abdomen or closest accessible subQ site to the injury (though systemic distribution means proximity matters less than for localized joint issues) Duration: 68 weeks loading phase, reassess at week 8 Most people notice reduced nerve pain and improved mobility within 24 weeks
Related Content Advertisement
In standard 7H9 media vadK , vadK:vadK His422Ala , vadK:vadK His422Asp and vadK:vadK Arg106Lys Mtb strains grew slower than the parental and complemented strains, but after 21 days incubation, there was no significant differences between the strains (Appendix Fig
Future risks remain unclear, especially in people with a history of cancer or vascular issues